Liquid Biopsy Technology Gets First US Patent From BIOCAPTIVA

BIOCAPTIVA has secured its inaugural US patent for a groundbreaking liquid biopsy technology designed to extract cell-free DNA (cfDNA) from bodily fluids with high efficiency. This innovation, developed from research at the University of Edinburgh, is set to enhance early disease detection, treatment oversight, and personalized medicine. This patent not only underscores BIOCAPTIVA's dedication to advancing its research but also opens doors for the technology’s broader applications in the biomedical sector.

Jeremy Wheeler, CEO of BIOCAPTIVA stated, “This US patent grant is a crucial achievement for BIOCAPTIVA. It not only secures our intellectual property but also underscores the extensive potential of our technology, which we've been developing since spinning out of the University of Edinburgh in 2020. What began as a focused research project and a single medical device has evolved into a comprehensive platform with far-reaching implications for liquid biopsy and the broader biomedical industry.”

BIOCAPTIVA's newly patented msX technology stands out for its ability to extract nucleic acids, especially cfDNA, from biological fluids like blood and plasma in significantly larger quantities than traditional methods. This innovative solution eliminates the need for centrifugation and additional reagents. The patent encompasses both in-vivo and ex-vivo uses, including the BioCaptis medical device aimed at enhancing cancer management.

The biotech firm is keen on exploring broader applications for this technology. Its capacity to efficiently capture nucleic acids from extensive volumes of fluids presents new opportunities for disease detection, treatment monitoring, personalized medicine, and advancing molecular diagnostics beyond cancer.